Ambaw Bellete

Chairman at

OncoSTING LLC

Net worth: - $ as of 31/05/2026

55 year

10 connections

Health Technology

Technology Services

Consumer Services

Profile

Ambaw Bellete is currently Chairman at OncoSTING LLC and Director at Axiom REACH Foundation.
Former roles include President & Chief Operating Officer at CG Oncology, Inc. (2023–2026), Chief Executive Officer at Lion Healthcare Strategies LLC (2021–2023), Head-US Cancer Commercial Operations at Photocure ASA, Trustee at BioNJ, Inc., President at MCS, Inc. (2012–2019), Chief Operating Officer at FerGene, Inc., and President at Photocure, Inc. (2012–2019).
Education includes undergraduate studies at Murray State University (Kentucky).

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
CG ONCOLOGY, INC. -.--%	15/04/2026	0 ( -.--% )	- $	31/05/2026

Ambaw Bellete active positions

Companies	Position	Start
OncoSTING LLC OncoSTING LLC OncoSTING LLC is an American biotechnology company focused on developing immunotherapies for bladder cancer and certain solid tumors. The company is located in the US. Its lead product, OS-151, is a second-generation, recombinant BCG-based therapy that combines traditional BCG immunotherapy with sustained delivery of potent STING agonists. This dual-action approach is intended to enhance efficacy while reducing adverse events compared to standard BCG treatment. OS-151 is being developed primarily for non-muscle invasive bladder cancer and as an intratumoral immunotherapy for tumors such as malignant melanoma.	Chairman	-

All active positions of Ambaw Bellete

Former positions of Ambaw Bellete

Companies	Position	End
CG ONCOLOGY, INC.	President	-
Photocure, Inc. Photocure, Inc. Hospital/Nursing ManagementHealth Services Operates as a bladder cancer company	President	01/08/2019
MCS, Inc. MCS, Inc. Information Technology ServicesTechnology Services Provides information systems and services to the home health care industry	President	01/07/2019
FerGene, Inc. FerGene, Inc. BiotechnologyHealth Technology Develops gene therapies for the treatment of unresponsive non-muscle invasive bladder cancer	President	-

See the detail of Ambaw Bellete's experience

Training of Ambaw Bellete

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Ambaw Bellete's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	8
MCS, Inc. MCS, Inc. Information Technology ServicesTechnology Services Provides information systems and services to the home health care industry	Technology Services
Photocure ASA Photocure ASA Medical SpecialtiesHealth Technology Develops and sells pharmaceuticals and medical devices	Health Technology
Murray State University (Kentucky) Murray State University (Kentucky) Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
BioNJ, Inc. BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services Promotes the biotechnology industry in New Jersey	Commercial Services
CG Oncology, Inc. CG Oncology, Inc. BiotechnologyHealth Technology Operates as a late-stage clinical biopharmaceutical company focused on developing and commercializing backbone bladder-sparing therapeutic	Health Technology
Photocure, Inc. Photocure, Inc. Hospital/Nursing ManagementHealth Services Operates as a bladder cancer company	Health Services
FerGene, Inc. FerGene, Inc. BiotechnologyHealth Technology Develops gene therapies for the treatment of unresponsive non-muscle invasive bladder cancer	Health Technology
OncoSTING LLC OncoSTING LLC OncoSTING LLC is an American biotechnology company focused on developing immunotherapies for bladder cancer and certain solid tumors. The company is located in the US. Its lead product, OS-151, is a second-generation, recombinant BCG-based therapy that combines traditional BCG immunotherapy with sustained delivery of potent STING agonists. This dual-action approach is intended to enhance efficacy while reducing adverse events compared to standard BCG treatment. OS-151 is being developed primarily for non-muscle invasive bladder cancer and as an intratumoral immunotherapy for tumors such as malignant melanoma.